Regeneron Pharmaceuticals
REGN
1,328 hedge funds and large institutions have $57B invested in Regeneron Pharmaceuticals in 2026 Q2 according to their latest regulatory filings, with 122 funds opening new positions, 481 increasing their positions, 540 reducing their positions, and 169 closing their positions.
1.38% more ownership
Funds ownership: 87.1% → 88.48% (+1.4%)
0% more call options, than puts
Call options by funds: $1B | Put options by funds: $999M
5% less funds holding
Funds holding: 1,398 → 1,328 (-70)
11% less repeat investments, than reductions
Existing positions increased: 481 | Existing positions reduced: 540
18% less capital invested
Capital invested by funds: $69.8B → $57B (-$12.8B)
28% less first-time investments, than exits
New positions opened: 122 | Existing positions closed: 169
63% less funds holding in top 10
Funds holding in top 10: 24 → 9 (-15)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Portfolio Management
Malvern,
Pennsylvania
|
+$990M |
| 2 |
Dodge & Cox
San Francisco,
California
|
+$281M |
| 3 |
SG Americas Securities
New York
|
+$183M |
| 4 |
Nordea Investment Management
Stockholm,
Sweden
|
+$183M |
| 5 |
WorldQuant Millennium Advisors
New York
|
+$172M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$467M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$441M |
| 3 |
Capital World Investors
Los Angeles,
California
|
-$411M |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
-$386M |
| 5 |
JP Morgan Chase
New York
|
-$366M |
REGN Hedge Fund Activity: Q2 2026 in Review
1,328 of the 8,279 institutional investors tracked by Wall St. Rank reported a position in Regeneron Pharmaceuticals (REGN) for Q2 2026, worth a combined $57B — down 18% from $69.8B a quarter earlier.
Sellers outnumbered buyers: 169 funds closed out of REGN and 122 opened new positions — a net loss of 47 holders — while 540 trimmed existing stakes and 481 added.
The largest buyer was Vanguard Portfolio Management, adding an estimated $990M. The largest seller was Fidelity Investments, cutting an estimated $467M.
- 1,328 institutional investors held Regeneron Pharmaceuticals (REGN) as of Q2 2026, down from 1,398 in Q1 2026.
- Funds reported $57B of Regeneron Pharmaceuticals stock for Q2 2026, down 18% quarter-over-quarter.
- 122 funds opened new Regeneron Pharmaceuticals positions in Q2 2026 and 169 closed out, a net change of -47 holders.
- The largest Regeneron Pharmaceuticals buyer in Q2 2026 was Vanguard Portfolio Management, an estimated $990M added.
- The largest Regeneron Pharmaceuticals seller in Q2 2026 was Fidelity Investments, an estimated $467M sold.
Based on aggregated 13F filings for Q2 2026.